NPCE - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to NeuroPace’s Second Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Matt Bacso from the Gilmartin Group for a few introductory comments.

Matt Bacso

Thank you, operator. Good morning and thank you for participating in today’s call.

are CEO NeuroPace CFO. Rebecca from me Mike and Favet, Kuhn, Joining today, for XXXX. results released quarter Earlier financial XX, the NeuroPace ended June A release website. copy press on of company’s the is available the

assumptions. to and you those Private guidance, impact our Before our from statements, the I’d Harbor in uncertainties to product during call Litigation laws, trends expansion place on or meaning differ or current materially operating hiring, will Reform of should estimates recovery, are management, XXXX. performance, and revenue financial we that of future call Accordingly, the results which predictions and pipeline trials expectations provisions the Securities around will business forward-looking within forward-looking events federal to relate you are actual in like events, upon remind expectations future opportunity, these These statements Safe commercial this Any on statements statements could begin, include of statements. make that to growth are of statements to the management clinical market this forward-looking that contained expense those for for statements. prospects of based reliance cause including Act and securities pursuant or that not material development organization, by COVID-XX our results these and implied NeuroPace’s undue relating and risks performance involve All those forward-looking statements. various made our

update with Rule June SEC on or in and including SEC Risk future. Factors filings our file our risks uncertainties pursuant reports XXXX of well by reports the new or or to with may the only turn And the will please that or descriptions XXX(b)(X) over with live financial the SEC, we Mike. disclaims time-sensitive as with statements, Exchange business, refer public or quarterly Form required forward-looking the events detailed I XX, with to This of XXXX. NeuroPace future believe of intention filed now because broadcast information, Commission, any as that, of any and more any to law, contains is August the otherwise. our which projections as the on conference Securities the revise For we on whether as accurate call section associated except X, call obligation, XX-Q to information,

Mike Favet

Thanks, Matt. afternoon you Good for us. and thank joining

growing to quarter second company, therapy suffering to our our life-changing a operating momentum and continue hope epilepsy. dedication I discuss we on people from focus As sense public bringing and as to

we to are their on following quarter reducing stage suffering people commercial Although in line just with by IPO the company eliminating first call June epilepsy one-third cover and company X.X medications to transforming epilepsy as available earnings considered people of a overview updates debilitating And lives United occurrence the seizures. of epilepsy. of Roughly while business drugs drug-resistant, before today’s or recently a approximately April, with quarterly is unable are living held in results. first are because I’ll device are treatment, from focused call NeuroPace our antiepileptic the with control States seizures. start in on brief medical a our moving people million

a United States. As result, approximately in drug-resistant there living the are epilepsy million people X.X with

regain a lives their full As reach to we strive patients potential. and company, their help epilepsy

brain-responsive first eliminate commercially and the platform, available or debilitating neuromodulation to only is System reduce occurrence seizures. RNS of Our the designed

personalized seizures real time to source, to patterns programmed responding monitors activity and start. at Our patient-specific before is by the with the loop The brain recognize seizures. treatment associated able preventing to device device deliver then is continuously close they in

while unprecedented records also normal visibility insights providing their can physicians live they activity outcomes. optimize seizure giving lives, patterns therapy patients System as to use unique ongoing brain RNS into Our patients’

our While expand a time, to indication drug-resistant with we use broader epilepsy into over adults for is intend treat patients. our focal to set current indication of epilepsy

We our begin drug-resistant to have XX epilepsy and enrollment a ages XX expect patients year. to study IDE indication to clinical focal to later for expand approval this

Additionally, and potential to most epilepsy, shortly generalized describe, type the expansion indication as into will intend second I we epilepsy. common of pursue

The years faster, cognition recordings improved results have enduring at our reported with all reduction from living conducted drug-resistant improvements across effectiveness brain, with clinical time. and follow-up for of follow-up. study seizure offers median an The after the the that patient of brain therapy focal epilepsy. improvements developed years life unique study reduction reduction We cohorts In retrospective real-world through seizure X that in demonstrated a the approval in largest demonstrate System RNS System utility X seizure even and in epilepsy, XX% our outcomes an driving better results quality demonstrating with conducted study of prospective of of extensive evidence, more body published areas RNS recently over of our in significant and longest FDA neuromodulation adults

patients. innovate more the information can their intracranial of RNS diary the the seizure progress, use to records. launch to of These burden. believe physicians counsel System, recordings, EEG with and which for device. continue capabilities X example for X% effectiveness recording to monitor which platform, have obtaining platform routine. our their broad data patients in-person with nSight view patient’s along coverage available for is a data the Hospital allows better improve than approval us physician improve has living programming And for drug-resistant System. help System been policies coverage to our parameters to One of is we from established is they RNS physician believe information, them that of RNS therapy We implant giving provide integrates our Reimbursement products epilepsy. that patients’ recordings, unique programming learn is brain portal provide comprehensive of to periodic capabilities less continue and indicated System. competitive activity denied RNS seizure our an of RNS and the a the our become more advantage, EEG for people and broadly recent the optimize reimbursement the of We with online clinicians extensive data place, or also us review set, patient million positive by in brain also allow our our remote than leveraging We with and with which implantation analytics includes believe

the unique primarily second XX.X% to results, by a in a million, and COVID-impacted am compared compared of On the $XX.X of This representing through total NeuroPace of quarter of first basis, growth the times. XXXX. sales unit sequential our to report XX% increase to increase these challenging the second successfully procedures. severely of System revenues was that the pleased revenues XXXX. to turning navigate RNS Now, continued QX for We to implant an XXXX, driven throughout quarter I team increased initial reported quarter

During the second number RNS comprehensive and to to have epilepsy track quarter, the in System implanting centers on we able XXX XXXX. increase of remain and were centers plant our

RNS roughly during epilepsy June, diagnostic mentioned until the EMU it takes unit initial X monitoring our from of we months evaluation System. last or our call implantation inpatient earnings in As

take months prerequisite diagnostic recent Given evaluations have fewer this patient continue means resulting the RNS physician including saw Delta as to fewer their of XXXX candidates Fewer the the the evaluation, RNS EMUs patients lag, in and through as summer we some a the have second our between measured patients patient number that admission forecasting identified in in evaluations increased COVID-XX headwinds the COVID-XX System. continues XXXX. from vacations System for diagnostic variant. of impact business the forward but months, diagnostic first volumes, recovery moved time for and in potential EMU of half we In EMU to patients the journey, the approach in and coming few and the implant months, being given

million we of revenue, XX% an increase implant first the second XXXX. quarter of reported of $X.X compared to XXXX and quarter XX% to the Additionally, of compared replacement

last rates expiration implanted in in can replacement over XX% is higher of approximately This have previously primarily the function devices. battery quarters Given years, planned seen than lower replacement we implant revenue a replacement or the with several result revenue.

pleased replacement generally years introduced that due over battery, we in which to to replacement decrease several it are a the transition important we quarter, with in revenue implant to revenue expect the next remember we the is longer-lasting second the XXXX. While to

I an initiate would to to update we Next, provide like on clinical plan quarters. the in coming trials the

between lag for mentioned, to approval to enrollment contribution we previously drug-resistant focal study expand a year, IDE We expect for and to ages younger approximately the the on and this track end revenue indication XX. of RNS our System to implant. XX before given epilepsy study XXXX this initiate patients clinical As enrollment X-month remain to continue minimal for have patient

known XXXX. for device We also designation RNS to study believe primary patients us idiopathic would our System enrollment epilepsy, to FDA FDA We in breakthrough XXXX, otherwise track position before the generalized with proposal remain the as IDE on submit an received of end to which epilepsy. we the from generalized begin in

patients to We indication. in late improve that and of onset summarize, current causes the States, do the up to which outcomes of received be LGS. centers, the of System We XXXX. LGS an United devastating funding announced that to continue epilepsy revenue in to Research CECs or innovations Additionally, frequent to study, half is this believe to and grant we primary injury. use investing these will grow NIH feasibility Syndrome seizures these is increased in in treat RNS initiate plan Advancing to of all focus June, our in that provide years at ease to to patients neuromodulation expanding which will to often funds utilization enrolling LGS BRAIN through use evaluate NeuroPace To use. an evaluate is to with generalized or second X a lead million increasing our to form referrals that onset of and device over a into Lennox-Gastaut we initiative $X.X Neurotechnologies, Innovative childhood driving projected our first in and dysfunction cognitive IDE the Brain intend patient the by start

our also with the investing expand to United indications exploring epilepsy potential are with opportunities outside and We generalized younger patients epilepsy, focal to States. patients

patients I with early are With Chief we brain benefits Finally, bring supporting Financial turn other NeuroPace’s disorders. therapy the to over that, Rebecca, neuromodulation to work the Officer. will of feasibility call that responsive the could

Rebecca Kuhn

sequential quarter epilepsy for to In XXXX, centers the the our Thanks million unit for increase second basis, System initial over $X.X Mike. implant RNS XX% NeuroPace’s the was driven an of compared quarter, million, replacement of the revenue XX%. revenue million quarter The of of quarter primarily Revenue XXXX. an compared revenue was increase a by increased to $XX.X of from of XXXX initial first XXX% procedures. quarter the second of implants comprehensive sales XXXX. implant of $X.X an XXXX. $X.X increase On to the quarter second XX% second was increase of compared from second to was for implants million, initial increase in an

to next generally replacement we the expect transition second a XXXX the implant due years for As continue second XX% of quarter stated, battery. was revenue to to margin for several XXXX. decrease Gross of Mike XX.X% longer-lasting compared in the to the quarter to

the XXXX, million million $X.X increase the pandemic. in the increase the XXXX. as of salary period margin pandemic, implemented $XX in the prior in cost The compared $X.X same in R&D expense compensation negatively of improved year. volume in increased. In XXXX gross XXXX, cost-cutting of the to period was our and impacted measures production XXXX, was to as In reductions, primarily COVID manufacturing second by in of resulting Total of R&D million due lower volume quarter in reduced the $X.X of furloughs our operating quarter in COVID-XX driven the number unit temporarily lower production gross operating quarter per were expenses primarily of quarter million quarter temporary we in by a idled second to XXXX response Our with the was margin compared same the due fixed an expense second expenses. second second was of expenses. with including

as The the saw in compared associated by second increase company. in we an prior year XXXX expense period. product of operating development increase was million Additionally, in and in in driven was compensation $X.X the expenses study primarily public an clinical $X.X and quarter million with increase SG&A with costs expenses. SG&A a

the from marketing saw second million million year also quarter non-cash final and return operations We other with sales, travel, in charge restrictions period. ease $X.X we to a in in warrant conducting This was to XXXX. of expenses, at an more the due non-recurring the initial of customers. compared million the our In as Loss field public million recorded costs, support increase of our $X.X $X.X fair of and exercised million COVID-XX of in-person including IPO. visits to prior in to we for resulting quarter an offering. were preferred quarter was the convertible $X.X from value liability loss increase warrants our second the compared is time $X.X XXXX of as expense in the second XXXX Net

cash and Our long-term June of investments balance borrowings XX, million, million. $XXX.X our was totaled as short-term $XX.X XXXX while

like to XXXX our outlook. I’d provide update to an Now

this, hospital, While risks growth year on a approximately and uncertainties total given revenue second measured posed continue XX% approach compared take we COVID-XX, the expect representing impact year behavior. new continue and on our patient to were quarter by variants we Based of with full pleased we the including million, full of to $XX results, to physician the XXXX. surrounding potential

implant expect and trial which minimal We represents year $XX revenue revenue full approximately initial includes million, of XXXX. to of compared clinical XX% growth

replacement will XXXX. now This to approximately call million, $XX revenue representing open mentioned a over Mike our prepared who turn to would call the to year replacement anticipate for given operator, XX% questions. the the of concludes revenue previously, compared remarks. dynamics full back be the we decline I like to Lastly,

Operator

line Thank JPMorgan. comes from Instructions] with you. Our Robbie question [Operator Marcus first the of

Unidentified Analyst

the say on Hi, great I guys. Alan congrats Robbie. This actually want is quarter. for on to

obviously think hospitals, I impact lot the moving deferring elective some room especially a of the of in thinking are is Just with the to states elephant about kind right investors of what now with off start COVID-XX, procedures. towards some

of in you versus your inpatient So to of third Delta seeing and have seen you respect with what forward-looking the with are on in what respect seeing demand quarter and far what trends? are COVID so impact to like yourselves, terms your you capacity

Mike Favet

Great. Thanks for the question.

wanted go some business. directly, I the I to take fundamentals to of Before a minute of it answer the back to

our really initial growth for doubling initial business. fundamental So, let appreciate the which that prepared the pleased in that the QX implant reported long-term and me remarks start saw, and over the QX, over of are with of driver procedures, implant of strength the are driven we especially some XXXX XX% We we of revenue just QX. by as reiterating I growth thanks sequential on that performance your

uncertainty the QX. physicians country, last really top That’s in off for what we the from patients for in device that elephants schedules in investing – couple from driven that, business, mentioned, utilization for place, coming an reimbursement elective Delta data the by start indication to by procedure last position saw headwinds of that’s implant weeks, said, grounded we’ve that have elective the weeks, especially COVID-XX business stay. Additional seen we in weeks of and growth of then across certain increasing have a centers established, seen to the room what well within And much strong as within procedures color that, in really, both associated are the that And regions putting and wanted our long-term growth. the our the as organization. – and variants the on is part behind sheet the like the the of that vacation as long long-term as greater in those balance of And these see historically. of what in last limitations all on the that with higher as more extent there of enabled which the of well growth that we in that drivers Really, implanting to future really was couple with than that’s that ICU the couple of really for initial that of of procedures us centers limited fundamentals are the that on we’ve implications clinical fundamentally – we’ve require the started business. you to in that keep just expansions, reemergence with a

talked started And impact do with and transitory know last don’t our implications, fact, it’s those a factors the the these they we point those that. year While for of the impact full way regional impact that for I greater in said, believe saw in but we place. recovery assumes going being much Delta That procedures the were elective that potential associated the kind we uncertainty the last end to saw of magnitude when that once system impact. that hospital that’s are completed the degree. again, of recently through point, before I allow that at year. to very or It’s in very how more its on providing we we’re happen procedures this those emerging of limitations works this of to year, business, have so guidance an nature. the The At like what with any long to variant about

talked there and coming COVID, patients So we impacts other that procedures through could they work be will while then of of as impact past happen, the that may the the around year. is this And when are in be we’ve system well there about those the epilepsy which their way monitoring expect unit. timing through

to this us We’ve March the really in during of had we those year. reduced second a started the Delta to too understand how expect difference, those be through know to first long us are much yet. too don’t going going early I’d associated in We for see maintain. of to number recovery on quarter of at coming seeing that end be, an of the know many with the of than how ways, variant. patients this EMU. starting impact EMU this number I reported of at what early talking you’re the have of the to. We been other a no nature, that but impact half XXXX, year in or for transitory to the patients point, impact that It’s to that say is Again, admissions companies

Unidentified Analyst

to to quick channel grow more improvement then Thank into are the able crossed, this, so fingers kind hopefully, an really how much issue feet ‘XX in And COVID of you just much. so and when and of as it. running? your XQ able are start continued environment, Delta you of in of awareness and less you’re referral this get and Got XXXX, challenging a follow-up, in drive kind

Mike Favet

Thanks.

So things doing here to place, to this out. there of to of referring restrictions that by awareness. referral out through COVID. awareness and we’re the reaching to more doing around point, is even the Delta travel piloting we’ve don’t able anticipate those of hasn’t as to variant physicians community, of additional if And physician the the relates community patient we’re the media But visits the education in do our and put restrictions and as it some the We’ve that A be of through that do to ability capability in digital have been remotely. relates ability the direct-to-patient got travel it more as that, come in that as impacted remote well awareness education person education as – more by the physicians development, efforts will impacted been I awareness, specifically. lot in

Operator

Thank you.

from comes question next Wells with line of Biegelsen the Fargo. Our Larry

open. now is line Your

Unidentified Analyst

will This let of guess to in QX versus QX we in entered QX assume does how then And should taking about could likely that those began the and in it when if or benefited [indiscernible] Is Larry. because step-up respect be just and much masked next should from cadence a QX with the for backlog. was actually the the trends think QX fair? I And wondering implants? QX? sales I reflects know is sound into it how question. for the who COVID probably headwinds think we it half, impact in you you like us Thank will second you replacement year. then to in QX of COVID ease QX headwinds EMUs do

Mike Favet

Thanks for question. the

RNS deferred if starting our of know, And EMU. pent-up driven So around any saw – and System starting I considered year. through demand. I by with this, me of the say, through question would to QX last of pipeline let were is missed in just this in – of the – patients business of year implant the as through of be with QX last for patients from patients coming the year, with works, recovery We your year, QX the impact really, the coming but last that on

of in patients so And were deferred QX year. QX, that last patients really that we those surge in of captured

last our centers, So fundamentals the year business, an levels. was increase specifically. the of in through to business the wasn’t of longer-term started It pre-pandemic year, getting driver in the just mentioned, QX per late of second see, the numbers QX pent-up as performance through more the closer growth and a by March of adding to utilization I demand coming QX patients those We’ve driven That EMU, center. this is more quarter of business. for a

up. the of prepared to business, your We’re of pockets had in or couple really weeks, for – the patients across the last surgery. COVID-XX through quarter, will started there on developing, Delta in more the on couple that’s as country, half last are pent-up happened to limitations both overall. as monitor variant mentioned to but uncertainty in of again, the whether restrictions to that some in that seen just vacations have coming And goes headwinds monitoring we’re the elective now, on remarks, the we from related the question, – as it’s Right late third have of If sorry, happen. in see will patients up, impact but coming far the procedural started the through EMU, then year, that weeks, last coming that impact last had continuing about now as second weeks, EMU well not – And through and is the more then the couple COVID-related come question coming for limited physicians. that in as of within we’ve coming literally that whether

So those that, system. our they’ll as that QX. will transitory a to But again, in is there be COVID-XX relates then, those assumptions be are themselves fair whether that’s monitoring short-term that work that assumption. see is expectation in the And the to impact, with and it through we whatever relatively that place headwinds for that nature obviously, impact our and will

Unidentified Analyst

you. Thank

Operator

you. Thank

Our next question comes from the with line Morgan of Ranieri Stanley. Drew

line open. Your now is

Drew Ranieri

Hi, everyone. Thanks for taking the questions.

specifically second the was utilization. hoping Mike, driving to I Just more bit in color just what’s specifically the little strength get the quarter, to on a quarter, underlying to

you’re of users adoption Just more your existing of a it your is curious epilepsy RNS land more expand kind more and of center? comprehensive at a or of if becoming their function or function a increase seeing

Mike Favet

had growth centers that saw provided implanting Thanks utilization. device, the increase in guidance We we as to of XXXX. Drew. expecting from the as The that QX in well to we’re both centers came from XXX number implanting more

overall, that We within continue in continue and the to track that driving utilization that those combination the the saw expect centers. are increasing implanting utilization of that’s With to centers implanting growth we of that’s implanting within in that, a more then come that the of QX. the our bulk time, we also, within those number to be greater is from center, from growth And so those over physicians system. but said, device. trend amount And each the and utilization centers coming increase from, NeuroPace making of will the are centers on

the within centers. trend to we So we an the continue. a the from expect number of coming again, centers, utilization And that’s growth see did in the increase that bulk but of

Drew Ranieri

future it, the you. us line just can a helpful? many of time you enroll a you soon, And expect would this And you Got or milestones be and the both coming moment, in with maybe studies patients time provide at could give maybe of studies beyond pipeline any to primary details that? those just for that just thank on focal adolescent, generalized how

Mike Favet

Yes.

The with have the approved Let me start studies. we adolescent the that. study, for IDE adolescent

process started We’re in the through trial. working that getting enrollment of

the here to of continue will We start installment expect half second in that the that, year.

mentioned the patient delta baseline activity in collected the shouldn’t is I baseline, is is that, this the implanted. the device minimal a we’re prepared because impacts they variant, a I a implanted use in Delta study that’s year. there for the X-month X-month – the that’s patient study. delta in with between when between expecting study period And there delay As and enrolled about a of each patient remarks, a when really the With enrollment from adolescent seizure before get revenue is

requires approved patients and So a our for X followed for we primary expanding minimal delayed year, that The expecting XX that of impact study. study have minimum implant, half then in in will for – second start adolescent will study year of the in with we this enrollment requires to revenue the from the be be year. next that study endpoint

generalized enrollment over XXXX. So again, the place next in year we following with and those implanting patients, will the enrolling to be expected those that patients to Switching of take bulk the are we the device generalized that working that breakthrough a the study primary that trial. on study trial, epilepsy received that’s we for idiopathic study, generalized design epilepsy of or designation

engaged what of submitting to there second size don’t forward need follow-up and we magnitude I this amount I with the be just looking year. here to the that later as the and uncertainty year of again, what we have is is approval half IDE the will the going approval. what described large exactly here for tell what that FDA But similar proposing can the is you FDA to submission that Because that engaging IDE is. We’re on in to FDA some we for with be study the is adolescent to that’s sample make about and how of anticipate this the something FDA to yet,

Drew Ranieri

Great. the taking Thanks it. for questions, Mike. Appreciate

Mike Favet

Yes, Drew. thanks,

Operator

you. Thank

comes Our Leerink. SVB with of line last question Danielle the Antalffy from

Your line open. is now

Danielle Antalffy

Mike, like quarter. question, questions. the sort and new Thank of a for going? how a multiple your getting more you. afternoon Maybe everyone. and what’s around is to And process surgeons taking a opening take? to how define just a for new this what so on reps to the scale, process Like you’re centers? referring? of then seeing much you you’re the how good bit little second but strong – does follow-up Congrats Drew’s long epileptologists to centers a would Hi, it Sort as get however question scale, for very that center you up of sales implanting the getting

Mike Favet

Danielle. Thanks,

drug-resistant in the includes patients that set of implant increase been And also recently first really RNS all for engaged wants of it they with engaged a those the implanting a that we’ve but growth centers ultimately, the centers centers, patients. some treatment to long we’ve create number, a is just the that for us, that patients, time, we’ve epilepsy started of as identify some it for first created through combination and, process in that There their with. interest from in So program requires to set patients. them of go that get of a comes number the that

road show we of contracts both. engaged we’ve it’s in the pipeline accounts place. have We with And had to been and of that combination leading up so that have the the and a a in IPO talked

it’s and through very that and and implanted. of And come coming move that. and patients so are first that getting through to is been move we’ve centers increase do that have a engaged identified quickly to unable lot with for sometimes centers But then process matter that we those those on a a contracting of while, from

of to expressing that So actually initially variability takes and get somebody there implant. from long long way is interest saying of first lot doing it their to a is how

make to in continuing We’re growth that.

those we’re number time. of And seeing so expanding centers over the

XXX implanted. to grow We’re expecting centers year last

we XXXX that into supporting to We’re be we we’ve a in expecting go again, year. the gotten up continue that with that XXX that to centers us level point those to accounts beyond. have – have with as others to engaged go again, will increase that engaged this are been a have recent process. the number center while in And having with, And pipeline some and that of to of and are more relatively some mixed for

Danielle Antalffy

Got it.

necessarily why a that in dilutive question number little And think higher? wouldn’t And I I numbers these of asked. get year Okay. do of answer the the go the you But that question guess for I new my utilization in even to to of But you guidance, tied know and on if basically, are we and the as coming the don’t just were implanting stable I the to you seems end the online just saw by what just get guidance maybe And follow-up to and year, dilutive half initially, maybe half QX utilization I pretty back from is even it wouldn’t XXX think is would bit to know love because sort why a any to on suggest in QX. perfect higher it’s then back you accounts. QX relates the where centers aren’t color implanting but accounts. be question the than

Mike Favet

question, Yes. for the Thanks Danielle.

So center of bit time number at average detail centers. number per we period a look longer modest. of centers year is per of maybe of We implants implanting about it’s relatively the around number the implanting of the still over little talk because when a

the for relatively We’re in adoption those phase early centers.

the I’m full implanting the XXXX, in centers when number so of that’s the about of And centers year number in XXXX. talking implanting

end some and and of the year. others QX centers so just And toward will of and have start implanted those QX come and in on will the QX, implanting

a for is the to we’re out that see there said, little bit that So math overall, guess, in way that. increase an nuance, continuing utilization. works with I the With of

annual XXXX as going over continues increase in increase on XXXX it if If And of a the of an at quarter half is terms look you the a rolling basis, you to well. utilization. that second four on basis in at it basis, XX-month look rolling year or

I just don’t it’s little that if makes centers based may report looking the that implanting know if that bit way So be on but average utilization. we number a of confusing, of at the sense. the

Danielle Antalffy

on That’s Thank center the commentary. the that’s new No, helpful. for you Thank helpful. reminder you. selected

Operator

to for are questions There remarks. call now time. closing over the you. Thank this no turn further Mike I will at Favet

Mike Favet

meeting that’s conferences would events to time for if all thank industry today. for I We you like taking or some in-person you great and Rebecca Thank look the with available. to forward future, Have your evening. time us. the you in a at Thanks. hopefully,

Operator

conference this and participation. your call. today’s gentlemen, concludes for you Ladies Thank

now disconnect. may You

NeuroPace (NPCE) 14 Aug 212021 Q2 Earnings call transcript